Role of Human Resistin in Insulin Resistance
Role of Human Resistin in Insulin Resistance
批准号:
8433834
负责人:
MITCHELL A. LAZAR
金额:
$33.29万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-09-01 至 2017-05-31
关键词:
AddressAdipocytesBacterial Artificial ChromosomesBioinformaticsBiological MarkersCardiovascular DiseasesCellsCessation of lifeChronicClinical ResearchComplexCongestive Heart FailureDataDevelopmentDiabetes MellitusDietDiseaseEndotoxinsEpidemicEpidemiologic StudiesEpidemiologyEvaluationExposure toFatty acid glycerol estersFunctional disorderFundingGenesGeneticGenomicsGoalsHeart failureHistone AcetylationHot SpotHumanHypoglycemiaInflammationInflammatoryInstructionInsulinInsulin ResistanceInterventionLinkMetabolicMetabolic DiseasesModelingMolecularMorbidity - disease rateMusNon-Insulin-Dependent Diabetes MellitusNutritionalObesityPhysiologicalPhysiologyPredispositionPrincipal InvestigatorProteinsRegulationResistanceRoleSeveritiesSocietiesSpecificityStimulusTestingTransgenesUnited Statesadipokinesbaseblood glucose regulationcysteine-rich secreted protein FIZZ3cytokinedeletion analysisepigenomicsglucose and insulin clampsglucose metabolismhuman diseaseinnovationinsightinsulin signalinginterestmacrophagemortalitynovelnovel therapeuticsprogramsresistinstemtranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Diabetes is a leading cause of morbidity and death in the United States. Type 2 diabetes, the most common
form, is associated with obesity and characterized by resistance to the actions of insulin. Although the
underiying mechanisms are complex and controversial, it is now clear that type 2 diabetes is a chronic
inflammatory state, and that inflammation modulates glucose metabolism. We were first to describe a novel
secreted protein called resistin that exacerbates insulin resistance. In mice, resistin is adipocyte-specific and
expressed constitutively, but human resistin is produced predominantly by macrophages and induced by
nflammatory stimuli. Epidemiologic and genetic evidence supports a role for resistin in human diabetes and
cardiovascular disease, and we have demonstrated that macrophage-derived human resistin is sufficient to
exacerbate diet-induced insulin resistance. However, the metabolic effects of inflammation-induced resistin
are not known. We now have established an innovative humanized resistin model in which mice lacking
mouse resistin express low circulating levels of resistin that increase with high fat diet and after exposure to
endotoxin. Specific Aim 1 is to determine the impact of humanized resistin expression on obesity- and
inflammation-associated insulin resistance. We hypothesize that humanized resistin expression induces
insulin resistance that is chronically deleterious but protective hypoglycemia, and will evaluate this using
innovative models of inflammation interrogated by glucose and insulin clamp studies. Specific Aim 2 is to
determine the effects of humanized resistin expression on cardiovascular disease. We hypothesize that the
humanized expression of resistin will exacerbate heart failure, and will test this in appropriate models.
Specific Aim 3 is to detennine the mechanism of species- and cell-specificity of resistin expression, applying
an innovative epigenomic discovery approach will to this important problem. Together, the proposed studies
will address critical questions about the role of resistin as a link between inflammation, insulin resistance,
and cardiometabolic diseases, and a potential target for intervention in these devastating diseases. These
studies have important implications for our society in which metabolic diseases are rampant.
RELEVANCE (See instructions):
Diabetes is a leading cause of morbidity and death in the United States. Type 2 diabetes, the most common
form of diabetes, is associated with obesity and characterized by resistance to the actions of insulin.
Understanding the mechanism of insulin resistance is critical to finding new therapies. We are determining
the role of resistin, which exacerbates insulin resistance and is induced by inflammation in humans. Resistin
may be a target for novel therapies that stem the tide of the epidemic of metabolic disease in our society.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PPARa and related nuclear receptors in non-alcoholic fatty liver disease
-
批准号:10210669
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2021
-
负责人:MITCHELL A. LAZAR
-
依托单位:
PPARa and related nuclear receptors in non-alcoholic fatty liver disease
-
批准号:10372221
-
项目类别:
-
资助金额:$35.75万
-
财政年份:2021
-
负责人:MITCHELL A. LAZAR
-
依托单位:
PPARa and related nuclear receptors in non-alcoholic fatty liver disease
-
批准号:10576286
-
项目类别:
-
资助金额:$35.75万
-
财政年份:2021
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Thyroid hormone receptors - regulation and function
-
批准号:8010993
-
项目类别:
-
资助金额:$9.95万
-
财政年份:2010
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Genome-wide epigenetic control of circadian metabolism by heme receptor Rev-erb
-
批准号:7817388
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Univ of Pennsyvania Diabetes Endocrinology Res Ctr
-
批准号:7980511
-
项目类别:
-
资助金额:$31.87万
-
财政年份:2009
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Genome-wide epigenetic control of circadian metabolism by heme receptor Rev-erb
-
批准号:7934606
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Nuclear Receptor Coregulator Functional Pathology in Metabolic Disease
-
批准号:7350615
-
项目类别:
-
资助金额:$28.85万
-
财政年份:2007
-
负责人:MITCHELL A. LAZAR
-
依托单位:
ADMINISTRATIVE CORE
-
批准号:7283873
-
项目类别:
-
资助金额:$45.01万
-
财政年份:2007
-
负责人:MITCHELL A. LAZAR
-
依托单位:
ROLE OF RESISTIN IN INSULIN RESISTANCE
-
批准号:7486267
-
项目类别:
-
资助金额:$30.55万
-
财政年份:2007
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Differentiated funtion of tissues involved in nutrition and metabolism
-
批准号:7499959
-
项目类别:
-
资助金额:$7.64万
-
财政年份:2007
-
负责人:MITCHELL A. LAZAR
-
依托单位:
ACADEMIC ENRICHMENT PROGRAM
-
批准号:7283881
-
项目类别:
-
资助金额:$11.87万
-
财政年份:2007
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Differentiated function of tissues involved in nutrition and metabolism
-
批准号:7138747
-
项目类别:
-
资助金额:$193.64万
-
财政年份:2006
-
负责人:MITCHELL A. LAZAR
-
依托单位:
ADMINISTRATIVE CORE
-
批准号:7215490
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2006
-
负责人:MITCHELL A. LAZAR
-
依托单位:
ROLE OF RESISTIN IN INSULIN RESISTANCE
-
批准号:7215485
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2006
-
负责人:MITCHELL A. LAZAR
-
依托单位:
Differentiated function of tissues involved in nutrition and metabolism
-
批准号:7288251
-
项目类别:
-
资助金额:$188.51万
-
财政年份:2006
-
负责人:MITCHELL A. LAZAR
-
依托单位:
REGULATION OF ADIPOCYTE DIFFERENTIATION BY RETINOIC ACID
-
批准号:6344798
-
项目类别:
-
资助金额:$12.62万
-
财政年份:1999
-
负责人:MITCHELL A. LAZAR
-
依托单位:
REGULATION OF ADIPOCYTE DIFFERENTIATION BY RETINOIC ACID
-
批准号:6201914
-
项目类别:
-
资助金额:$12.62万
-
财政年份:1999
-
负责人:MITCHELL A. LAZAR
-
依托单位:
REGULATION OF ADIPOCYTE DIFFERENTIATION BY RETINOIC ACID
-
批准号:6105663
-
项目类别:
-
资助金额:$12.62万
-
财政年份:1998
-
负责人:MITCHELL A. LAZAR
-
依托单位:
University of Pennsylvania Diabetes Research Center
-
批准号:8469468
-
项目类别:
-
资助金额:$182.18万
-
财政年份:1997
-
负责人:MITCHELL A. LAZAR
-
依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
-
批准号:81970721
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:陶凌
-
依托单位: